Valneva SE American Depositary Shares (VALN)
Stock · NASDAQ · Health Care
$5.61as of 10/16/2026
Price chart
Active signals
VALN Signal Track Record
How signals performed across all stocks →What VALN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | +6.4% | 62% | October 5, 2026 |
| Bollinger Band Breakdown | 21 | -4.2% | 43% | October 1, 2026 |
| Bollinger Band Breakout | 20 | -4.3% | 30% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +4.8% | 67% | July 2, 2025 |
| Any 20-session window (baseline) | -3.1% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VALN
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing entero…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 620
- Website
- valneva.com/
Fundamentals
- 1-day range
- $5.58$5.8
- Market cap
- $491.51M
- P/E (trailing)
- —
- P/E (forward)
- 4.69
- EPS (trailing)
- $-1.09
- Dividend yield
- —
- Beta
- 0.72
- Avg. volume
- 75.5K
Forecasts
4 analyst ratings
Valneva SE American Depositary Shares Competitors
Chosen by industry and closest market cap.
- VALNValneva SE American Depositary Shares$5.61▼ 5.08%Market cap $491.51MP/E —$2.03$5.15
- PROKProKidney Corp. Class A Ordinary Shares$1.33▼ 8.59%Market cap $495.38MP/E —$1.3$3.48
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
- KYTXKyverna Therapeutics Inc. Common Stock$5.67▼ 5.03%Market cap $471.16MP/E —$5.61$13.67
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VALN Valneva SE American Depositary Shares | $491.51M | — | $5.61 | ▼ 5.08% | $2.03$5.15 |
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.33 | ▼ 8.59% | $1.3$3.48 |
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
| KYTX Kyverna Therapeutics Inc. Common Stock | $471.16M | — | $5.67 | ▼ 5.03% | $5.61$13.67 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Full Transcript: Valneva Q2 2026 Earnings Callbenzinga · 10/14/2026
- UK Revokes Approval for Valneva's Chikungunya ShotBenzinga · 10/8/2026
- Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya VaccineYahoo · 10/8/2026
- VALN Stock Plunges 7% After-Hours As UK Revokes Valneva’s IXCHIQ Authorization In Latest Market SetbackYahoo · 10/7/2026
- Valneva ADRs fall as UK revokes IXCHIQ marketing authorizationYahoo · 10/7/2026
- Valneva Provides Update on IXCHIQ® in the United KingdomYahoo · 10/7/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 10/7/2026
- Declaration of shares and voting rights - Status as of September 30, 2026Yahoo · 10/5/2026
- Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?Yahoo · 9/24/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 3.91M
- Total value held
- $24.30M
- Institutional holders
- 21
- Unknown2.29M
- Unknown1.06M
- Unknown354.4K
- Unknown78.0K
- Unknown46.9K
- Unknown25.1K
- Unknown20.8K
- Unknown13.8K
- Unknown10.0K
- Unknown5.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Valneva mentioned in XFG vaccine formula article
A recent article discusses a new vaccine formula called XFG and its potential impact on Pfizer and BioNTech. Valneva is mentioned in this context, though the primary focus of the report is on the other two companies. This news provides broader industry context for the vaccine sector rather than specific corporate developments for Valneva.
Valneva mentioned in XFG vaccine formula article. A recent article discusses a new vaccine formula called XFG and its potential impact on Pfizer and BioNTech. Valneva is mentioned in this context, though the primary focus of the report is on the other two companies. This news provides broader industry context for the vaccine sector rather than specific corporate developments for Valneva.